Form 4: Halozyme Therapeutics Director Henderson Acquires Shares and Options

Director Jeffrey William Henderson acquired shares and options in Halozyme Therapeutics, Inc. on May 1, 2025, according to a Form 4 filing.

Summary

• On May 1, 2025, Jeffrey William Henderson, a director of Halozyme Therapeutics, Inc., acquired 4,165 shares of common stock and an option to purchase 5,750 shares.
• The common stock was acquired through a restricted stock unit (RSU) grant under the issuer's director compensation program.
• The RSU grant will vest in full on the earlier of May 1, 2026, or the date of the issuer's next annual meeting of stockholders.
• The option to purchase common stock has an exercise price of $60.03 and expires on May 1, 2035.
• This option grant will vest in full on the earlier of May 1, 2026, or the date of the issuer's next annual meeting of stockholders.
• Following these transactions, Henderson beneficially owns 32,776 shares of common stock and options to purchase 5,750 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The director's acquisition of shares and options suggests confidence in the company's future, but it's a routine transaction.

Positives

• Director Henderson's acquisition of shares and options signals confidence in Halozyme's future prospects.

Future Outlook

The RSU and option grants will vest on the earlier of May 1, 2026, or the date of the next annual meeting of stockholders.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology industry, where stock options and restricted stock units are commonly used to align the interests of directors and shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotech industry, similar to companies like Amgen and Gilead Sciences.
• The vesting schedule of one year is fairly standard, aligning with industry norms for incentivizing long-term performance.
• The exercise price of $60.03 for the options would need to be compared to the current market price of Halozyme's stock to assess its potential value.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment, as it indicates confidence from a member of the board of directors.
• There is no immediate impact on employees, customers, suppliers, or creditors.

Next Steps

• Monitor Halozyme's stock performance and any further insider transactions.
• Await the next annual meeting of stockholders to determine the actual vesting date of the RSU and option grants.

Key Dates

Keywords

Halozyme Therapeutics, Director, Henderson, Stock Options, RSU, Beneficial Ownership, Form 4, Securities